One Of The Five Cyclos Is Five-membered And Includes Ring Chalcogen (e.g., Codeine, Morphine, Etc.) Patents (Class 514/282)
-
Publication number: 20130251801Abstract: The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.Type: ApplicationFiled: May 23, 2013Publication date: September 26, 2013Applicant: Purdue Pharma L.P.Inventors: William H. McKenna, Richard O. Mannion, Edward P. O'Donnell, Haiyong H. Huang
-
Publication number: 20130251800Abstract: The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.Type: ApplicationFiled: May 23, 2013Publication date: September 26, 2013Applicant: Purdue Pharma L.P.Inventors: William H. McKenna, Richard O. Mannion, Edward P. O'Donnell, Haiyong H. Huang
-
Publication number: 20130251789Abstract: Disclosed is an oral dosage form comprising: (i) an opioid agonist in releasable form and (ii) a sequestered opioid antagonist which is not released when the dosage form is administered orally intact.Type: ApplicationFiled: December 18, 2012Publication date: September 26, 2013Applicant: PURDUE PHARMA L.P.Inventors: Benjamin OSHLACK, Curtis WRIGHT, J. David HADDOX
-
Publication number: 20130251799Abstract: The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.Type: ApplicationFiled: May 23, 2013Publication date: September 26, 2013Applicant: Purdue Pharma L.P.Inventors: William H. McKenna, Richard O. Mannion, Edward P. O'Donnell, Haiyong H. Huang
-
Publication number: 20130251798Abstract: The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.Type: ApplicationFiled: May 23, 2013Publication date: September 26, 2013Applicant: Purdue Pharma L.P.Inventors: William H. McKenna, Richard O. Mannion, Edward P. O'Donnell, Haiyong H. Huang
-
Publication number: 20130251797Abstract: The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.Type: ApplicationFiled: May 23, 2013Publication date: September 26, 2013Applicant: Purdue Pharma L.P.Inventors: William H. McKenna, Richard O. Mannion, Edward P. O'Donnell, Haiyong H. Huang
-
Publication number: 20130251812Abstract: Disclosed is an oral dosage form comprising (i) an opioid agonist in releasable form and (ii) a sequestered opioid antagonist which is substantially not released when the dosage form is administered intact, such that the ratio of the mean Cmax of the antagonist after single dose oral administration of the dosage form after tampering to the mean Cmax of antagonist after single dose oral administration of an intact dosage form is at least 1.5:1.Type: ApplicationFiled: May 22, 2013Publication date: September 26, 2013Applicant: Purdue Pharma L.P.Inventors: Christopher Breder, Benjamin Oshlack, Curtis Wright
-
Publication number: 20130252995Abstract: Compositions, uses, kits and methods for reducing binge or compulsive eating are described herein. Methods may include administering an effective combination of a dosage of a bupropion or a pharmaceutically acceptable salt thereof, and a dosage of naltrexone or a pharmaceutically acceptable salt thereof. Methods may include identifying a patient who is overweight or obese and providing an effective combination of bupropion and naltrexone to the patient. Methods may include reducing a number of binge or compulsive eating events. Methods may include reducing severity of binge or compulsive eating events.Type: ApplicationFiled: December 2, 2011Publication date: September 26, 2013Applicant: OREXIGEN THERAPEUTICS, INC.Inventors: Eduardo Dunayevich, Susan Mcelroy, Ron Landbloom
-
Patent number: 8541026Abstract: The present invention relates to SRSR solid dosage forms for administering pharmaceutical agents, particularly Hydrocodone and acetaminophen, methods for preparing the dosage forms, and methods for providing therapeutic agents to patients in need of treatment.Type: GrantFiled: April 20, 2007Date of Patent: September 24, 2013Assignee: AbbVie Inc.Inventors: Yihong Qiu, Cheri E Klein
-
Publication number: 20130244985Abstract: Effective treatments of pain and/or inflammation are provided. Through the administration of an effective amount of at least analgesic and/or at least one anti-inflammatory agent at or near a target site, one can reduce, prevent or treat inflammation and pain.Type: ApplicationFiled: May 10, 2013Publication date: September 19, 2013Applicant: Warsaw Orthopedic, Inc.Inventor: William F. McKay
-
Publication number: 20130245056Abstract: Disclosed are compositions, uses, methods and kits for increasing drug bioavailability in a naltrexone therapy.Type: ApplicationFiled: December 2, 2011Publication date: September 19, 2013Applicant: Orexigen Therapeutics, Inc.Inventors: Shawn Flanagan, Eduardo Dunayevich
-
Publication number: 20130245055Abstract: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.Type: ApplicationFiled: May 9, 2013Publication date: September 19, 2013Applicants: PURDUE PHARMACEUTICALS L.P., THE P.F. LABORATORIES, INC.Inventors: Curtis Wright, Benjamin Oshlack, Christopher Breder
-
Publication number: 20130245054Abstract: The present invention relates to storage stable prolonged release pharmaceutical dosage forms comprising oxycodone or a pharmaceutically acceptable salt thereof and naloxone or a pharmaceutically acceptable salt thereof, the manufacture thereof as well as their use for administration to human beings.Type: ApplicationFiled: August 11, 2011Publication date: September 19, 2013Inventors: Derek Allan Prater, Christof Spitzley, Gerhard Heun, Alexander Schütz, Udo Hahn, Christian Leuner
-
Patent number: 8536192Abstract: A novel compound which is useful as an agent for treating and/or preventing emesis, vomiting and/or constipation. A compound represented by the formula (I): wherein R1 and R2 are each independently hydrogen, optionally substituted lower alkyl, optionally substituted lower alkenyl, optionally substituted cycloalkyl, optionally substituted aryl etc., R3 is hydrogen, hydroxy, optionally substituted lower alkyl, optionally substituted lower alkenyl, optionally substituted lower alkynyl, optionally substituted lower alkoxy etc., R4 is hydrogen or lower alkyl, R5 is hydrogen, lower alkyl, cycloalkyl lower alkyl or lower alkenyl, or a pharmaceutically acceptably salt, or a solvate thereof is provided.Type: GrantFiled: November 30, 2011Date of Patent: September 17, 2013Assignee: Shionogi & Co. Ltd.Inventors: Masanao Inagaki, Shin-ichiro Hara, Nobuhiro Haga, Yoshinori Tamura, Yoshihisa Goto, Tsuyoshi Hasegawa
-
Patent number: 8536191Abstract: The present invention is directed to novel crystalline and amorphous forms of nalbuphine hydrochloride.Type: GrantFiled: July 21, 2011Date of Patent: September 17, 2013Assignee: Noramco, Inc.Inventors: Jason Hanko, Petinka Vlahova
-
Publication number: 20130236524Abstract: Implants for delivery of therapeutic agents such as opioids, and the manufacture and uses of such implants are provided. In particular, subcutaneous drug delivery systems having a biocompatible thermoplastic elastomeric polymer matrix, a therapeutic agent embedded homogeneously in said matrix, and a biocompatible drug impermeable cross-linked silicone polymer coating said matrix and methods of making the same are provided.Type: ApplicationFiled: September 7, 2012Publication date: September 12, 2013Applicant: AXXIA PHARMACEUTICALS, LLCInventors: Richard J. HOLL, Katherine HARTMAN, Stuart A. Grossman, Wayne C. Pollock
-
Publication number: 20130237558Abstract: The present invention relates generally to a sterile hydromorphone hydrochloride solution that is substantially free of buffer.Type: ApplicationFiled: March 6, 2013Publication date: September 12, 2013Applicant: Mallinckrodt LLCInventors: John J. Foster, Thomas R. Prentice
-
Patent number: 8530495Abstract: The present invention relates to the Nalmefene hydrochloride dihydrate, methods of manufacturing Nalmefene hydrochloride dihydrate, a pharmaceutical composition comprising Nalmefene hydrochloride dihydrate and a method of treatment comprising administering Nalmefene hydrochloride dihydrate.Type: GrantFiled: December 4, 2009Date of Patent: September 10, 2013Assignees: H. Lundbeck A/S, Bioei Therapies CorpInventors: Heidi Lopez de Diego, Carla de Faveri, Florian Anton Martin Huber
-
Publication number: 20130230596Abstract: An opioid-antagonist oral dosage form which does not release a therapeutically effective amount of the opioid antagonist when the oral dosage form is orally administered to a human being, but whereby a physical alteration of the oral dosage form results in a release of the therapeutically effective amount of the opioid antagonist. An embodiment of the oral dosage form includes an opioid-antagonist layer coated onto a biologically inert pellet, and a non-releasing membrane coated onto the opioid-antagonist layer. Optionally, the oral dosage form can also include an opioid agonist, such that a method of preventing the abuse of an oral dosage form of an opioid agonist is provided by forming the oral dosage form including an opioid agonist and an opioid antagonist.Type: ApplicationFiled: April 16, 2013Publication date: September 5, 2013Applicant: Elite Laboratories, Inc.Inventor: Atul M. Mehta
-
Patent number: 8524277Abstract: A membrane system comprising an interior wall, a fluid-permeable exterior wall surrounding the interior wall and an internal compartment defined by the membrane system, wherein fluid permeability of the interior wall is responsive to osmolarity of an osmotic core within the internal compartment are disclosed. A controlled release dosage form comprising the membrane system and a process for delivering an osmotically active formulation from an osmotic pump over an extended period of time are also disclosed.Type: GrantFiled: February 9, 2007Date of Patent: September 3, 2013Assignee: Alza CorporationInventors: David E. Edgren, Patrick S.-L. Wong, Gurdish K. Bhatti, Shu Li, Robert R. Skluzacek
-
Patent number: 8524731Abstract: The invention provides methods of attenuating, e.g., inhibiting or reducing, cellular proliferation and migration, particularly endothelial cell proliferation and migration, including that associated with angiogenesis, using opioid antagonists, including, but not limited to, those that are peripherally restricted antagonists.Type: GrantFiled: April 17, 2006Date of Patent: September 3, 2013Assignee: The University of ChicagoInventors: Jonathan Moss, Mark Lingen, Patrick A. Singleton, Joe G. N. Garcia, Chun-Su Yuan
-
Patent number: 8524275Abstract: Disclosed in certain embodiments is an oral dosage form comprising a therapeutically effective amount of an opioid analgesic, an opioid antagonist and one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid.Type: GrantFiled: October 21, 2010Date of Patent: September 3, 2013Assignees: Purdue Pharma L.P., The P.F Laboratories, Inc., Purdue Pharmaceuticals, L.P.Inventors: Benjamin Oshlack, Curtis Wright, Christopher Breder
-
Publication number: 20130225625Abstract: The invention relates to a pharmaceutical dosage form having a breaking strength of at least 500 N and comprising a pharmacologically active compound, a polyalkylene oxide having an average molecular weight of at least 200,000 g/mol, and a nonionic surfactant; wherein the content of the polyalkylene oxide is within the range of from 20 to 75 wt.-%, based on the total weight of the pharmaceutical dosage form.Type: ApplicationFiled: February 27, 2013Publication date: August 29, 2013Applicant: GRUNENTHAL GMBHInventor: Grunenthal GmbH
-
Patent number: 8518962Abstract: Embodiments of the invention provide methods of attenuating, e.g., inhibiting or reducing, cellular proliferation and migration, particularly endothelial cell proliferation and migration, including that associated with angiogenesis, as well as attenuating cancerous tumor growth and metastasis, using opioid antagonists, including, but not limited to, those that are peripherally restricted antagonists.Type: GrantFiled: March 12, 2010Date of Patent: August 27, 2013Assignee: The University of ChicagoInventors: Jonathan Moss, Mark Lingen, Patrick A. Singleton, Joe G. N. Garcia
-
Patent number: 8518925Abstract: The present invention relates to an opioid controlled release oral dosage form comprising at least one opioid for the manufacture of a medicament to treat patients with Chronic Obstructive Pulmonary Disease (COPD).Type: GrantFiled: June 8, 2005Date of Patent: August 27, 2013Assignee: Euro-Celtique S.A.Inventors: Wolfgang Fleischer, Karen Reimer, Petra Leyendecker
-
Publication number: 20130217716Abstract: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.Type: ApplicationFiled: December 24, 2012Publication date: August 22, 2013Applicants: PURDUE PHARMA L.P., Purdue Pharmaceuticals L.P., The P.F. Laboratories, Inc.Inventor: Purdue Pharma L.P.
-
Publication number: 20130209557Abstract: The invention relates to a pharmaceutical dosage form exhibiting a breaking strength of at least 500 N, said dosage form containing a pharmacologically active ingredient (A); an inorganic salt (B); and a polyalkylene oxide (C) having a weight average molecular weight of at least 200,000 g/mol, wherein the content of the polyalkylene oxide (C) is at least 20 wt.-%, based on the total weight of the dosage form; wherein the pharmacologically active ingredient (A) is present in a controlled-release matrix comprising the inorganic salt (B) and the polyalkylene oxide (C) and wherein, under in vitro conditions, the release profile of the pharmacologically active ingredient (A) from said matrix comprises at least a time interval during which the release follows zero order kinetics.Type: ApplicationFiled: March 1, 2013Publication date: August 15, 2013Applicant: GRUNENTHAL GMBHInventor: GRUNENTHAL GMBH
-
Publication number: 20130210835Abstract: A composition of an antitussive, a decongestant, or an antihistamine to treat respiratory and oral pharyngeal congestion and related symptoms in a patient.Type: ApplicationFiled: June 13, 2011Publication date: August 15, 2013Applicant: GM PHARMACEUTICAL, INCInventor: Odes W. Mitchell
-
Publication number: 20130210853Abstract: The present invention is directed to a buprenorphine sustained release delivery system capable of delivering buprenorphine, a metabolite, or a prodrug thereof for a duration of about 14 days to about 3 months. The buprenorphine sustained release delivery system includes a flowable composition and a solid implant for the sustained release of buprenorphine, a metabolite, or a prodrug thereof. The implant is produced from the flowable composition. The buprenorphine sustained release delivery system provides in situ 1-month and 3-month release profiles characterized by an exceptionally high bioavailability and minimal risk of permanent tissue damage and typically no risk of muscle necrosis.Type: ApplicationFiled: June 6, 2011Publication date: August 15, 2013Applicant: RB PHARMACEUTICALS LIMITEDInventors: Richard L. Norton, Andrew Watkins, Mingxing Zhou
-
Publication number: 20130210701Abstract: Pharmaceutical compositions and their methods of use are provided, where the pharmaceutical compositions comprise an opioid prodrug that provides enzymatically-controlled release of an opioid, and an enzyme inhibitor that interacts with the enzyme(s) that mediates the enzymatically-controlled release of the opioid from the opioid prodrug so as to attenuate enzymatic cleavage of the opioid prodrug.Type: ApplicationFiled: November 27, 2012Publication date: August 15, 2013Applicant: SIGNATURE THERAPEUTICS, INC.Inventor: Signature Therapeutics, Inc.
-
Publication number: 20130209560Abstract: This disclosure relates to a sustained-release oral dosage form suitable for twice-a-day administration comprising a matrix containing a viscosity modifier and coated granules containing hydrocodone. The dosage form can have a release profile such that 6 hours following administration, less than about 80 percent of the hydrocodone is released. In addition, the dosage form may have alcohol and/or crush resistance.Type: ApplicationFiled: February 23, 2011Publication date: August 15, 2013Applicant: CIMA LABS Inc.Inventors: Ehab Hamed, Carrie Kraling
-
Publication number: 20130209561Abstract: We provide a pharmaceutical dosage form including an opioid antagonist surrounded by a controlled release matrix and an opioid agonist in a surrounding matrix.Type: ApplicationFiled: February 21, 2013Publication date: August 15, 2013Applicant: Endo Pharmaceuticals Inc.Inventor: Endo Pharmaceuticals Inc.
-
Publication number: 20130209525Abstract: Sustained release dosage forms for twice daily oral dosing to a human patient for providing relief from pain are provided. The sustained release dosage form comprises an immediate release component and a sustained release component, wherein the immediate release component and the sustained release component collectively contain a therapeutically effective amount of an opioid analgesic and a therapeutically effective amount of nonopioid analgesic. In a preferred embodiment, the nonopioid analgesic is acetaminophen and the opioid analgesic is hydrocodone and pharmaceutically acceptable salts thereof, and in preferred embodiments, the pharmaceutically acceptable salt is bitartrate. The dosage forms produce plasma profiles in a patient characterized by a Cmax for hydrocodone of between about 0.6 ng/mL/mg to about 1.4 ng/mL/mg and an AUC for hydrocodone of between about 9.1 ng*hr/mL/mg to about 19.9 ng*hr/mL/mg (per mg hydrocodone bitartrate administered) and a Cmax for acetaminophen of between about 2.Type: ApplicationFiled: February 28, 2013Publication date: August 15, 2013Applicant: ALZA CORPORATIONInventor: ALZA CORPORATION
-
Publication number: 20130210700Abstract: Pharmaceutical compositions and their methods of use are provided, where the pharmaceutical compositions comprise a phenol-modified opioid prodrug that provides enzymatically-controlled release of a phenolic opioid, and an enzyme inhibitor that interacts with the enzyme(s) that mediates the enzymatically-controlled release of the phenolic opioid from the phenol-modified opioid prodrug so as to modify enzymatic cleavage of the phenol-modified opioid prodrug.Type: ApplicationFiled: November 27, 2012Publication date: August 15, 2013Applicant: Signature Therapeutics, Inc.Inventor: Signature Therapeutics, Inc.
-
Publication number: 20130210854Abstract: The present disclosure provides pharmaceutical compositions, and their methods of use, where the pharmaceutical compositions comprise a prodrug that provides enzymatically-controlled release of a drug and an enzyme inhibitor that interacts with the enzyme(s) that mediates the enzymatically-controlled release of the drug from the prodrug so as to attenuate enzymatic cleavage of the prodrug. The disclosure provides pharmaceutical compositions which comprise an enzyme inhibitor and a prodrug that contains an enzyme-cleavable moiety that, when cleaved, facilitates release of the drug.Type: ApplicationFiled: December 7, 2012Publication date: August 15, 2013Applicant: SIGNATURE THERAPEUTICS, INC.Inventor: Signature Therapeutics, Inc.
-
Publication number: 20130203797Abstract: A therapeutic or prophylactic agent for biliary tract diseases includes as an effective component a specific compound having a morphinan skeleton represented by Compound 1, or a pharmaceutically acceptable acid addition salt thereof:Type: ApplicationFiled: January 28, 2011Publication date: August 8, 2013Applicant: TORAY INDUSTRIES, INC.Inventors: Ryosuke Kobayashi, Kaoru Nakao
-
Publication number: 20130195951Abstract: The present invention comprises compositions, methods and kits for delivering drugs. The invention provides an implantable device for delivery of a pharmaceutical substance to a patient, comprising a core comprising a core polymeric material optionally containing a core pharmaceutical substance, surrounded by a first layer comprising a first-layer pharmaceutical substance and a first-layer polymeric material, optionally surrounded by one or more additional layers comprising an additional pharmaceutical substance and an additional polymeric material, where the core, first, and optional additional polymeric materials may be the same or different, and where the optional core pharmaceutical substance, first-layer pharmaceutical substance, and optional additional pharmaceutical substances are the same or different. Implantation of the device allows a controlled release of drug for an extended period of time. The device may be implanted subcutaneously in an individual in need of continuous treatment with a drug.Type: ApplicationFiled: March 13, 2013Publication date: August 1, 2013Applicant: Titan Pharmaceuticals, Inc.Inventor: Titan Pharmaceuticals, Inc.
-
Publication number: 20130197021Abstract: The present invention relates to prolonged release pharmaceutical dosage forms, the manufacture thereof as well as their use for administration to human beingType: ApplicationFiled: May 10, 2011Publication date: August 1, 2013Applicant: Euro-Celtique S.A.Inventors: Hassan Mohammad, Malcolm Walden, Geoffrey Gerard Hayes, Harjit Tamber
-
Publication number: 20130196849Abstract: The present invention relates to substituted cellulose acetates and methods of use thereof. One embodiment of the present invention provides a coating having a substituted cellulose acetate having a polar substituent that has an oxygen atom covalently bonded to a nonmetal selected from the group of sulfur, phosphorus, and boron; wherein the nonmetal is present in at least about 0.01% by weight of the substituted cellulose acetate.Type: ApplicationFiled: January 27, 2012Publication date: August 1, 2013Applicant: Celanese Acetate LLCInventors: Michael T. Combs, Thomas S. Garrett
-
Publication number: 20130195981Abstract: There is provided pharmaceutical compositions for the treatment of pain comprising a pharmacologically-effective amount of an opioid analgesic, or a pharmaceutically-acceptable salt thereof, presented in particulate form upon the surfaces of carrier particles comprising a pharmacologically-effective amount of an opioid antagonist, or a pharmaceutically-acceptable salt thereof, which carrier particles are larger in size than the particles of the opioid analgesic. The compositions are also useful in prevention of opioid abuse by addicts.Type: ApplicationFiled: March 13, 2013Publication date: August 1, 2013Applicant: Orexo ABInventor: Orexo AB
-
Publication number: 20130195982Abstract: There is provided pharmaceutical compositions for the treatment of pain comprising a pharmacologically-effective amount of an opioid analgesic, or a pharmaceutically-acceptable salt thereof, presented in particulate form upon the surfaces of carrier particles comprising a pharmacologically-effective amount of an opioid antagonist, or a pharmaceutically-acceptable salt thereof, which carrier particles are larger in size than the particles of the opioid analgesic. The compositions are also useful in prevention of opioid abuse by addicts.Type: ApplicationFiled: March 13, 2013Publication date: August 1, 2013Applicant: Orexo ABInventor: Orexo AB
-
Publication number: 20130195935Abstract: A solid administration form, protected from parenteral abuse and containing at least one viscosity-increasing agent in addition to one or more active substances that have parenteral abuse potential. The agent forms, when a necessary minimum amount of an aqueous liquid is added, on the basis of an extract obtained from the administration form, a preferably injectable gel that remains visually distinct when introduced into another quantity of an aqueous liquid.Type: ApplicationFiled: March 14, 2013Publication date: August 1, 2013Applicant: GRUNENTHAL GMBHInventor: GRUNENTHAL GMBH
-
Publication number: 20130197020Abstract: A method of effectively treating pain in humans is achieved by administering buprenorphine in accordance with first order kinetics over an initial three-day dosing interval, such that a maximum plasma concentration from about 20 pg/ml to about 1052 pg/ml is attained, and thereafter maintaining the administration of buprenorphine for at least an additional two-day dosing interval in accordance with substantially zero order kinetics, such that the patients experience analgesia throughout the at least two-day additional dosing interval.Type: ApplicationFiled: October 29, 2012Publication date: August 1, 2013Applicant: PURDUE PHARMA L.P.Inventor: PURDUE PHARMA L.P.
-
Patent number: 8497287Abstract: The invention provides aminotetralin compounds of formula (I): wherein R1, R2, R3, R4, R5, R6, R7, n, and m are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are antagonists at the mu opioid receptor. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat conditions associated with mu opioid receptor activity, and processes and intermediates useful for preparing such compounds.Type: GrantFiled: October 17, 2012Date of Patent: July 30, 2013Assignee: Theravance, Inc.Inventors: Michael R. Leadbetter, Sean G. Trapp, Daniel D. Long, John R. Jacobsen, Sabine Axt
-
Patent number: 8497280Abstract: An analgesic composition, in parenteral unit dosage form or in a unit dosage form suitable for delivery via the dermis or mucosa, comprises buprenorphine and an amount nalmefene such that the ratio by weight of buprenorphine to nalmefene delivered to or reaching the plasma of a patient is in the range 22.6:1 to 40:1. The analgesic action of the buprenorphine is potentiated by the low dose of nalmefene. Also provided are a method of treatment of pain and the use of nalmefene and buprenorphine for the manufacture of a medicament.Type: GrantFiled: February 15, 2008Date of Patent: July 30, 2013Assignee: RB Pharmaceuticals LimitedInventors: Christopher Bourne Chapleo, Neil Hyde
-
Publication number: 20130189333Abstract: An oral product includes a body that is wholly receivable in an oral cavity. The body includes a mouth-stable polymer matrix, cellulosic fibers embedded in the mouth-stable polymer matrix, and an additive dispersed in the mouth-stable polymer matrix. The oral product is adapted to release the additive from the body when the body is received within the oral cavity and exposed to saliva.Type: ApplicationFiled: January 18, 2013Publication date: July 25, 2013Applicant: ALTRIA CLIENT SERVICES INC.Inventor: Altria Client Services Inc.
-
Publication number: 20130191933Abstract: Described herein are methods of treating nociception by administering to a subject in need thereof a therapeutic amount of one or more compounds which modulate the Hedgehog signaling pathway.Type: ApplicationFiled: June 7, 2011Publication date: July 25, 2013Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMInventors: Michael J. Galko, Daniel T. Babcock, Howard B. Gutstein
-
Publication number: 20130189342Abstract: The present invention comprises compositions, methods and kits for delivering drugs. The invention provides an implantable device for delivery of a pharmaceutical substance to a patient, comprising a core comprising a core polymeric material optionally containing a core pharmaceutical substance, surrounded by a first layer comprising a first-layer pharmaceutical substance and a first-layer polymeric material, optionally surrounded by one or more additional layers comprising an additional pharmaceutical substance and an additional polymeric material, where the core, first, and optional additional polymeric materials may be the same or different, and where the optional core pharmaceutical substance, first-layer pharmaceutical substance, and optional additional pharmaceutical substances are the same or different. Implantation of the device allows a controlled release of drug for an extended period of time. The device may be implanted subcutaneously in an individual in need of continuous treatment with a drug.Type: ApplicationFiled: March 16, 2011Publication date: July 25, 2013Applicant: TITAN PHARMACEUTICALS, INC.Inventors: Rajesh A. Patel, Sunil R. Bhonsle
-
Publication number: 20130190343Abstract: Methods and compositions are provided for preventing or reversing loss of the therapeutic effect of a drug, where the loss is associated with the repeated administration of the drug to a patient. The method includes administering to the patient a dopamine receptor agonist or partial agonist or a drug that increases the extracellular level of dopamine by enhancing release of dopamine, decreasing the removal of dopamine from the extracellular space, enhancing the synthesis of dopamine within the brain, or decreasing metabolic degradation of dopamine; and also administering to the patient an opioid receptor antagonist in an ultra-low dose amount, wherein the ultra-low dose amount is effective to prevent or reverse loss of therapeutic effects associated with the repeated administration of the drug to the patient. The methods are useful for various treatments, including treating Parkinson's Disease, Restless Leg Syndrome, depression, schizophrenia, psychostimulant drug abuse, or attention deficit disorder.Type: ApplicationFiled: February 4, 2013Publication date: July 25, 2013Inventors: David M. Bear, Robert M. Kessler
-
Publication number: 20130190342Abstract: The invention relates to a composition comprising buprenorphine and a ? opioid receptor antagonist, wherein the composition is characterized by an Agonist Antagonist Activity Index (AAnAI) of between about 0.7 and about 2.Type: ApplicationFiled: December 14, 2012Publication date: July 25, 2013Applicant: Alkermes Pharma Ireland LimitedInventor: Alkermes Pharma Ireland Limited